A new variant of the Covid-19 virus is rapidly spreading throughout the United States. Known as the BA.3.2 strain, also nicknamed Cicada, this variant was first identified in Africa in November 2024 before reaching the US in June 2025. It has been detected in patients and wastewater systems across 29 states nationwide.
Health experts have highlighted that the existing Covid-19 vaccines may not be as effective against the Cicada strain due to its significant genetic differences. However, there is currently no evidence suggesting that this variant poses a higher risk compared to more recent strains.
Cicada carries 70 to 75 genetic changes in the virus segment responsible for cell entry, which is crucial for vaccine effectiveness. As viruses evolve through genetic mutations during replication, certain changes may provide a competitive advantage, enabling the spread of specific variants.
The alterations in Cicada make it challenging for the immune system to identify the virus, potentially leading to broader infection rates among individuals. Despite its rapid transmission, there is no indication that Cicada causes more severe illness than other widely circulating Covid-19 variants.
Symptoms associated with Cicada are similar to typical Covid-19 cases and may include cough, fever, sore throat, congestion, fatigue, and loss of smell or taste. While symptoms can vary and often resolve with rest and over-the-counter treatments, asymptomatic infections are also possible, allowing the virus to spread unknowingly.
The NHS outlines potential Covid-19 symptoms, emphasizing the importance of monitoring for any signs of illness.
